The drug ent-verticilide reduced A-fib incidence and duration in an animal model, suggesting it may be a viable therapeutic option.
A technique to characterize all variants in genes associated with arrhythmia could improve the ability to identify and preemptively treat individuals at risk for sudden cardiac death.
Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.
Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.
Vanderbilt University Medical Center researchers have made a fundamental discovery about how the heart compensates for genetic variations that otherwise could trigger abnormal and potentially fatal heart rhythms.
Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities.